Paper Example Undergraduate 3,309 words

Venous Thromboembolism Vte in USA

Last reviewed: February 14, 2013 ~17 min read
Abstract

Venous Thromboembolism VTE is a disease that has been untapped for years. Many are also unaware that Venous thromboembolism is the leading cause of maternal death. Most people that are over the ages of 45 develop this disorder much more faster. This paper shows that the risk factors are much higher when the person is obese or if they have been up under surgery. This paper will explore Venous Thromboembolism VTE and its factors and influences.

Venous Thromboembolism VTE in USA

Venous Thromboembolism VTE is a disease that has been untapped for years. Many are also unaware that Venous thromboembolism is the leading cause of maternal death. Most people that are over the ages of 45 develop this disorder much more faster. This paper shows that the risk factors are much higher when the person is obese or if they have been up under surgery. This paper will explore Venous Thromboembolism VTE and its factors and influences.

In the United States, the wide prevalence of venous thromboembolism (VTE) is not very clear. VTE is the most serious complication many hospitalized patients encounter (Yokoyama, 2012). The has been a 5-year study of autopsy recorder that were connected with associated hospital records for 3000 autopsies gave the report that at least 10% of in-hospital deaths could be traced to venous thromboembolism. While the use of thromboprophylaxis approaches united with enriched patient care could lower the incidence of VTE over the years, venous thromboembolism is still seen as the most common avoidable causes of in-hospital demise in the United States. All of this means that venous thromboembolism considers being one of the major healthcare burdens in the U.S., predominantly among the elderly, and emphasizing an ongoing growth in occurrence of the disease (Michota, 2007). With that said, this paper discusses the nature of venous thromboembolism and its effect of different groups.

Definition

Venous thromboembolism (VTE) can be defined as a disease that comprises both pulmonary embolism (PE) and deep vein thrombosis (DVT). This disease is considered to be very common and deadly. A lot of people because of the lack of treatment and knowledge have died (Martinez- 2008). This typical disease is prevelant in hospitalized and non-hospitalized patients. It also happens often and is usually overlooked. This disease results in long-term problems as well as chronic thromboembolic pulmonary hypertension (CTPH) and the post-thrombotic syndrome (PTS). (Yokoyama, 2012)

Figure 1 this graph shows the ages affected by the disease.

Venous thromboembolism can be the results of combination between hereditary and acquired risk factors which is also recognized as thrombophilia or hypercoagulable states. Furthermore, venous stasis, vessel wall damage, and enlarged activation of clotting were issues that had been first defined by Rudolf Virchow more than a century ago continue to be the important foundation for people understands of thrombosis (Aujesky, 2007).

Natural history of venous thromboembolism

Venous thrombi, comprised predominately of red blood cells nonetheless also leukocytes and platelets bound together by fibrin, create in sites of vessel damage and areas of immobile blood movement for instance the valve pockets of the deep veins of the thigh or calve. Thrombi either stays all the way in the peripheral veins, where they sooner or later experience endogenous fibrinolysis and recanalization, or they embolize to the pulmonary arteries and create what is called the PE.

Host, agent and environmental factors

Age appears to be one of the strongest risk factors for thrombosis, with an abrupt incline of risk, where the incidence much higher in the very old than it is in people much younger. (Aujesky, 2007) it is not clear why venous thrombosis is a strong determinant. Several clarifications appear clear, every one of which perhaps add to some extent. These are reduced movement, a bigger incidence of risk-enhancing maladies, muscular tone that has been deceased, and attainment of other risk issues in addition to aging of the veins themselves, and predominantly of the valves that are located in the veins, that are vital for having a flow that is venous (Hyers, 2007).

Figure 2 this chart shows the number of risk factors with Venous Thromboembolism

Surgical interferences bring on an extremely high risk of thrombosis, which, reliant on the kind of surgery, may well happen in over 70% of the patients in the lack of antithrombotic prophylaxis (Martinez- 2008). Most of the risks that are high are consulted by neurosurgery and orthopedic surgery (Hyers, 2007). In surgery of the knee and hip, the risk of thrombosis gets to the point of around 40% to 60%.(Michota, 2007) Dangers that are approximately as high have been described for abdominal operation (up to 40%), urologic surgery and gynecologic surgery. (Michota, 2007) Usually, the greater the involvement, the bigger the risk, nonetheless in orthopedic surgery even slight involvements, for instance arthroscopy, significantly distress the danger of venous thrombosis (Maynard & Stein, 2010).

Prevalence and incidence

After acute coronary venous, thromboembolism is the third most common cardiovascular disease. Even though the precise incidence of VTE is not really known, it is supposed that there are about 2 million circumstances in the United States every year, a lot of these represent diseases that are recurrent (Maynard & Stein, 2010). Approximately two thirds of all Venous Thromboembolism measures outcome from hospitalization, and somewhere around 400,000 of these patients had died (Michota, 2007). The third most typical reason of hospital-related death and the most common avoidable cause of hospital-related death is called pulmonary embolism. (Hyers, 2007)a lot of patients that are in hospitals have many risk factors for Venous Thromboembolism (Yokoyama, 2012) Among patients in the hospital that have medical illness that appear to be acute, age >75, cancer, and a history of venous thromboembolism are normally linked with an increased Venous Thromboembolism danger. (Aujesky, 2007)Well-known and long-established cardiovascular risk factors counting cigarette smoking, hypertension, high cholesterol levels and diabetes mellitus have also been connected to acute PE. (Michota, 2007) Genetic risk issues for VTE comprise of factor prothrombin gene mutation G20210A, protein C. And S. deficiency, V Leiden, and anti-thrombin lack.

Figure 3 this graph shows the risk factors in the United States.

Clinical presentation and diagnosis (both DVT and PE)

The lesser limits are the most typical site for venous thromboembolism, but other affected places comprise of the mesenteric and pelvic veins and upper extremities and in addition to the cerebral veins. A proximal lower-extremity DVT is linked to an estimated 60% risk of pulmonary embolism (PE) if there is no treatment; whereas almost 25% to 30% of calf vein thrombi propagate (in the deficiency of treatment) to include the popliteal vein or that which was mentioned above (Michota, 2007). About 10% of all DVT cases normally have something to do with the upper extremities. Problems are much more typical succeeding DVT in the upper extremities instead of being in the lower part. Pulmonary embolism happens in among 8% and 14% of circumstances that shadow DVT in an upper extremity and in 25% to 40% of cases following DVT that takes place in the lower extremity. (Aujesky, 2007)

Figure 4 Use of prophylaxis for venous thromboembolism with patients.

Pulmonary emboli which results from lower extremity DVT normally have the prospective to guide to an amount of physiologic modifications because the pulmonary veins is blocked. These comprise of enlarged respiratory speed and hyperventilation, weakening of gas exchange because of decreased perfusion nevertheless not ventilation, intrapulmonary shunting leading to hypoxemia, and atelectasis and vasoconstriction which all result from the release of mediators that have become inflammatory (Michota, 2007).

In patients that are dealing with hemodynamically, intensely elevated pulmonary vascular resistance occurs in inside of the decreased right ventricular (RV) hypotension and output. To overpower the blocking thrombus and uphold pulmonary perfusion, the right ventricle will have to be able to produce systolic pressures in superfluity of mean pulmonary artery pressures larger than 40 mmHg and 50 mmHg. (Yokoyama, 2012) However, the normal right ventricle, nevertheless, is incapable when it comes to generating these pressures and right heart failure and cardiac collapse follows. Moreover, RV wall tension that has been raised could possibly lead to reduced right coronary ischemia and artery flow. Cardiopulmonary collapse from Pulmonary embolism is something more typical with a lot of patients that are older. However, this disorder also goes along with underlying cardiopulmonary disease or coexisting coronary artery disease. (Maynard & Stein, 2010)

Case ascertainment

To guarantee case ascertainment for venous thromboembolism was as thorough as possible, the researcher explored for incident cases purposely all through the study phase and retrospectively throughout and after the study phase.

Prospectively, the researcher recognized cases of venous thromboembolism in hospital patients from high-tech inpatient and attendance registers from emergency departments, lists of patients attending the Phoebe Putney Thrombosis Clinic, and lists of patients undergoing radiological tests. Patients with Venous Thromboembolism in the community were purposely determined by appealing to general doctors and privately functioned radiological facilities to signify patients to the small study, and by looking over the lists of patients in programs for nursing (Martinez- 2008). The researcher also put ads in community newspapers and the information sheet of a home nursing organization so that theoretically appropriate patients would be able to denote themselves to the study.

With that said, hospital patients for this study had been acknowledged by searching the hospital morbidity and death records of the Georgia Department of Health. Every one of the private and public hospices in a certain part of the state is necessary to submit data from the hospital to the Department of Health, where they are frequently organized. The researcher was able to pull up information on Venous Thromboembolism hospitalizations by utilizing ICD-10 (Maynard & Stein, 2010)

Diagnosis

The clinical diagnosis of Venous Thromboembolism is defective; people that are suffering with signs and symptoms of Venous Thromboembolism, just 20% have thrombosis confirmed by diagnostic testing.13Clinical prediction rules have been developed to improve the probability of an accurate diagnosis. The most widely used model classifies patients into a high, moderate, or low probability of deep vein thrombosis (Maynard & Stein, 2010). When joined with research laboratory and radiological imaging tests, this method is superior to the old-style method of executing a diagnostic test in all patients with suspected Venous Thromboembolism (Martinez- 2008).

Prognosis, broken down by risk groups

A lot of the Deep Vein Thrombosis is occult and most of the time resolves instinctively without there being a problem. The main longstanding illness from Deep Vein Thrombosis is PTS, which confuses something like half of cases of symptomatic proximal Deep Vein Thrombosis; a lot of these cases start developing in 2 years later. Demise from Deep Vein Thrombosis is credited to enormous Pulmonary embolism, which causes something like 400,000 deaths that occur every year in the United States. (Maynard & Stein, 2010) Pulmonary embolism is the leading aim of preventable in-hospital death. The Longitudinal Investigation of Thromboembolism Etiology (LITE) that combined statistics from two potential cohort investigations, the research determined that the incidence of symptomatic Deep Vein Thrombosis and Pulmonary embolism in 30,680 members that were aged 45 years and much or older that had been trailed for 8 years. (Hyers, 2007)

You’re 83% through this paper. Sign up to read the full paper.

Sign Up Now — Instant Access Already a member? Log in
130,000+ paper examples AI writing assistant Citation generator Cancel anytime
References
40 sources cited in this paper
  • Altom, L. K., Deierhoi, R. J., Grams, J., Richman, J. S., Vick, C. C., Henderson, W. G., . . . Hawn, M. T. (2012). Association between surgical care improvement program venous thromboembolism measures and postoperative events. The American Journal of Surgery, 204(5), 591-7.
  • Amin, A., Spyropoulos, A. C., Dobesh, P., Shorr, A., Hussein, M., Mozaffari, E., & Benner, J. S. (2010). Are hospitals delivering appropriate VTE prevention? the venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). Journal of Thrombosis and Thrombolysis, 29(3), 326-39.
  • Angchaisuksiri, P., Atichartakarn, V., Aryurachai, K., Archararit, N., Rachakom, B., Atamasirikul, K., & Tiraganjana, A. (2007). Risk factors of venous thromboembolism in thai patients. International Journal of Hematology, 86(5), 397-402.
  • Ashrani, A. A., Silverstein, M. D., Rooke, T. W., Lahr, B. D., Petterson, T. M., Bailey, K. R., . . . Heit, J. A. (2010). Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: A nested case-control study. Vascular Medicine, 15(5), 387-97.
  • Aujesky, D., Long, J. A., Fine, M. J., & Ibrahim, S. A. (2007). African american race was associated with an increased risk of complications following venous thromboembolism. Journal of Clinical Epidemiology, 60(4), 410-6.
  • Baglin, T., Luddington, R., Brown, K., & Baglin, C. (2003). Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. The Lancet, 362(9383), 523-6.
  • Barnes, G. D., Birkmeyer, N., Flanders, S. A., Froehlich, J. B., Hemmila, M., Henke, P. K., . . . Share, D. (2012). Venous thromboembolism: A collaborative quality improvement model for practitioners, hospitals, and insurers. Journal of Thrombosis and Thrombolysis, 33(3), 274-9.
  • Caprini, J. A., Arcelus, J., Sehgal, L. R., Cohen, E. B., & Reyna, J. J. (2002). The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. International Angiology, 21(1), 78-85.
  • Duran, A., Sengupta, N., Diamantopoulos, A., Forster, F., Kwong, L., & Lees, M. (2012). Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a US payer's perspective. PharmacoEconomics, 30(2), 87-101.
  • Farmer, R. D. T., Newson, R. B., MacRae, K., Lawrenson, R. A., & Tyrer, F. (1997). Mortality from venous thromboembolism among young women in europe: No evidence for any effect of third generation oral contraceptives. Journal of Epidemiology and Community Health, 51(6), 630-5.
  • Folsom, A. R., Cushman, M., Heckbert, S. R., Rosamond, W. D., & Aleksic, N. (2003). Prospective study of fibrinolytic markers and venous thromboembolism. Journal of Clinical Epidemiology, 56(6), 598-603.
  • Freeman, A. L. (2010). Prevention of venous thromboembolism in obesity. Expert Review of Cardiovascular Therapy, 8(12), 1711-21.
  • Ghanim, A. J., Daskalakis, C., Eschelman, D. J., & Kraft, W. K. (2007). A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. Journal of Thrombosis and Thrombolysis, 24(3), 247-54.
  • Gross, C. P., Galusha, D. H., & Krumholz, H. M. (2007). The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. Journal of General Internal Medicine, 22(3), 321-6.
  • Heit, J. A. (2003). The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolism*. Chest, 124(3), 40S-8S.
  • Hitos, K., & Fletcher, J. P. (2006). Venous thromboembolism following primary total knee arthroplasty. International Angiology, 25(4), 343-51.
  • Huo, M. H., & Spyropoulos, A. C. (2011). The eighth american college of chest physicians guidelines on venous thromboembolism prevention: Implications for hospital prophylaxis strategies. Journal of Thrombosis and Thrombolysis, 31(2), 196-208.
  • Hurewitz, A. N., Khan, S. U., Groth, M. L., Patrick, P. A., & Brand, D. A. (2011). Dosing of unfractionated heparin in obese patients with venous thromboembolism. Journal of General Internal Medicine, 26(5), 487-91.
  • Hyers, T. M., & Spyropoulos, A. C. (2007). Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. Journal of Thrombosis and Thrombolysis, 24(3), 225-32.
  • Lamberg, A. L., Horvath-puho, E., Christensen, S., & Sørensen, ,H.T. (2010). Use of oral bisphosphonates and risk of venous thromboembolism: A population-based case-control study. Osteoporosis International, 21(11), 1911-7.
  • Martínez-González, J., Vila, L., & Rodríguez, C. (2008). Bemiparin: Second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Review of Cardiovascular Therapy, 6(6), 793-802.
  • Maynard, G., & Stein, J. (2010). Designing and implementing effective venous thromboembolism prevention protocols: Lessons from collaborative efforts. Journal of Thrombosis and Thrombolysis, 29(2), 159-66.
  • Michota, F. A. (2007). Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: The quality improvement process. Journal of General Internal Medicine, 22(12), 1762-70.
  • Osborne, N. H., M.D., Wakefield, T. W., M.D., & Henke, P. K., M.D. (2008). Venous thromboembolism in cancer patients undergoing major surgery. Annals of Surgical Oncology, 15(12), 3567-78.
  • Otrock, Z. K., Taher, A. T., Shamseddeen, W. A., Zaatari, G., Bazarbachi, A., & Mahfouz, R. A. (2008). Factor V HR2 haplotype: A risk factor for venous thromboembolism in individuals with absence of factor V leiden. Annals of Hematology, 87(12), 1013-6.
  • Raftopoulos, I., Martindale, C., Cronin, A., & Steinberg, J. (2008). The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: A prospective comparison trial. Surgical Endoscopy, 22(11), 2384-91.
  • Rathbun, S. (2008). Venous thromboembolism in women. Vascular Medicine, 13(3), 255-66.
  • Reeves, D., & Liu, C. Y. (2010). Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. Journal of Oncology Pharmacy Practice, 16(1), 27-31.
  • Sasaki, S., Miyakoshi, N., Matsuura, H., Saito, H., Nakanishi, T., Kudo, Y., . . . Shimada, Y. (2011). Prospective study on the efficacies of fondaparinux and enoxaparin in preventing venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science, 16(1), 64-70.
  • Sasaki, S., Miyakoshi, N., Matsuura, H., Saitoh, H., Kudoh, D., & Shimada, Y. (2009). Prospective randomized controlled trial on the effect of fondaparinux sodium for prevention of venous thromboembolism after hip fracture surgery. Journal of Orthopaedic Science, 14(5), 491-6.
  • Satoh, T., Matsumoto, K., Uno, K., Sakurai, M., Okada, S., Onuki, M., . . . Yoshikawa, H. (2008). Silent venous thromboembolism before treatment in endometrial cancer and the risk factors. The British Journal of Cancer, 99(7), 1034-9.
  • Satoh, T., Oki, A., Uno, K., Sakurai, M., Ochi, H., Okada, S., . . . Yoshikawa, H. (2007). High incidence of silent venous thromboembolism before treatment in ovarian cancer. The British Journal of Cancer, 97(8), 1053-7.
  • Shih, R. A., Griffin, B. A., Salkowski, N., Jewell, A., Eibner, C., Bird, C. E., . . . Whitsel, E. A. (2011). Ambient particulate matter air pollution and venous thromboembolism in the women's health initiative hormone therapy trials. Environmental Health Perspectives, 119(3), 326-31.
  • Soto-Cárdenas, M., Pelayo-García, G., Rodríguez-Camacho, A., Segura-Fernández, E., Mogollo-Galván, A., & Giron-Gonzalez, J. (2008). Venous thromboembolism in patients with advanced cancer under palliative care: Additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliative Medicine, 22(8), 965-8.
  • Spencer, F. A., Emery, C., Joffe, S. W., Pacifico, L., Lessard, D., Reed, G., . . . Goldberg, R. J. (2009). Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. the worcester VTE study. Journal of Thrombosis and Thrombolysis, 28(4), 401-9.
  • Spencer, F. A., Kroll, A., Lessard, D., Emery, C., Glushchenko, A. V., Pacifico, L., . . . Goldberg, R. J. (2012). Isolated calf deep vein thrombosis in the community setting: The worcester venous thromboembolism study. Journal of Thrombosis and Thrombolysis, 33(3), 211-7.
  • Steele, K. E., Schweitzer, M. A., Prokopowicz, G., Shore, A. D., Eaton, L. C., B., . . . Magnuson, T. H. (2011). The long-term risk of venous thromboembolism following bariatric surgery. Obesity Surgery, 21(9), 1371-6.
  • Takahashi, H., Yokoyama, Y., Iida, Y., Terashima, F., Hasegawa, K., Saito, T., . . . Wada, A. (2012). Incidence of venous thromboembolism after spine surgery. Journal of Orthopaedic Science, 17(2), 114-7.
  • Wolowacz, S. E., Hess, N., Brennan, V. K., Monz, B. U., & Plumb, J. M. (2008). Cost-effectiveness of venous thromboembolism prophylaxis in total hip and knee replacement surgery: The evolving application of health economic modelling over 20 years. Current Medical Research and Opinion, 24(10), 2993-3006.
  • Zalavras, C. G., Giotopoulou, S., Dokou, E., Mitsis, M., & al, e. (2002). Lack of association between the C677T mutation in the 5, 10-methylenetetrahydrofolate reductase gene and venous thromboembolism in northwestern Greece. International Angiology, 21(3), 268-71.
Cite This Paper
PaperDue. (2013). Venous Thromboembolism Vte in USA. PaperDue. https://www.paperdue.com/essay/venous-thromboembolism-vte-in-usa-85926

Always verify citation format against your institution’s current style guide requirements.